CRIS Current Research Information System

AMABILE, MARILINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.143
EU - Europa 1.680
AS - Asia 697
AF - Africa 129
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.655
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.138
GB - Regno Unito 489
SE - Svezia 348
VN - Vietnam 249
CN - Cina 207
DE - Germania 207
IT - Italia 204
UA - Ucraina 102
IN - India 88
JP - Giappone 75
FR - Francia 66
IE - Irlanda 66
RU - Federazione Russa 56
TG - Togo 56
EE - Estonia 32
CI - Costa d'Avorio 30
JO - Giordania 30
ZA - Sudafrica 30
CH - Svizzera 29
BG - Bulgaria 21
BE - Belgio 18
GR - Grecia 17
FI - Finlandia 14
SG - Singapore 13
IR - Iran 11
TR - Turchia 9
NL - Olanda 7
SC - Seychelles 7
NG - Nigeria 6
CA - Canada 5
BR - Brasile 3
KR - Corea 3
PH - Filippine 3
BD - Bangladesh 2
CL - Cile 2
IL - Israele 2
LB - Libano 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
HK - Hong Kong 1
NO - Norvegia 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 4.655
Salva come PNG Salva come JPEG
Città #
Southend 443
Chandler 295
Fairfield 269
Ashburn 172
Woodbridge 141
Dong Ket 138
Houston 134
Seattle 129
Wilmington 129
Ann Arbor 107
Cambridge 90
Princeton 84
Jacksonville 71
Dublin 66
Tokyo 65
Lomé 56
Nanjing 41
Westminster 40
Padova 37
Turin 36
Beijing 31
Abidjan 30
Amman 30
New York 29
Berlin 25
Bern 25
Jinan 21
Saint Petersburg 21
Sofia 21
Bologna 19
Brussels 17
Bremen 16
Shenyang 16
Boardman 14
Helsinki 14
Milan 14
San Diego 14
Falls Church 12
Hebei 12
Medford 11
Washington 11
Nanchang 10
Taizhou 10
Dearborn 9
Des Moines 9
Florence 9
Haikou 9
Changsha 8
Jiaxing 8
Tianjin 8
Istanbul 7
Mahé 7
Mülheim 7
Rome 7
Abeokuta 6
Redmond 6
Singapore 6
Zhengzhou 6
Hangzhou 5
Leawood 5
Los Angeles 5
Norwalk 5
Pune 5
Castelfranco Emilia 4
Chiyoda-ku 4
Groningen 4
Mountain View 4
Olalla 4
Redwood City 4
Verona 4
Ferrara 3
Grafing 3
Guangzhou 3
Hamamatsu 3
Kashan 3
Kuban 3
Ningbo 3
Toronto 3
Andover 2
Athens 2
Bengaluru 2
Boston 2
Davao City 2
Dhaka 2
Frankfurt Am Main 2
Frankfurt am Main 2
Fuzhou 2
Kin 2
Kish 2
Kunming 2
La Spezia 2
Lanzhou 2
Mumbai 2
North York 2
Orange 2
Riolo Terme 2
San Venanzo 2
Tappahannock 2
Tel Aviv 2
Zanjan 2
Totale 3.199
Salva come PNG Salva come JPEG
Nome #
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 210
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 210
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 208
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 193
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 166
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 162
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 160
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 159
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 147
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 146
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 145
Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study 138
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 133
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 130
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. 129
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 121
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 120
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 116
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 116
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 114
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 112
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 106
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 105
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 103
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 100
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 98
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 97
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 92
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 87
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 85
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 85
null 79
null 77
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 75
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 74
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 68
Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study 68
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 60
null 57
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 47
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 35
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 26
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. 22
Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty 7
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 4
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia-positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24-homology domains but not the pleckstrin homology one 1
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia 1
Totale 4.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.231 157 25 13 91 164 134 149 149 145 76 47 81
2020/2021723 125 45 12 26 35 30 4 50 65 37 47 247
2021/2022924 102 13 56 106 79 68 18 52 35 83 160 152
2022/20231.088 125 217 55 140 56 91 36 48 174 20 89 37
2023/2024393 10 49 19 50 29 129 30 27 8 10 20 12
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 4.794